Mounjaro May Help Protect Heart Health in People With Type 2 Diabetes

Recent research has found that the popular GLP-1 medication, Mounjaro, may help lower heart attack risk in people with type 2 diabetes. Galina Zhigalova · Moment/Getty New research suggests the GLP-1 medication Mounjaro may lower the risk of heart attack and other major cardiovascular events in people with type 2 diabetes and established heart disease. Researchers estimated that for every 70 people who started tirzepatide, one major cardiovascular event could be prevented. The findings suggest tirzepatide may provide cardiovascular benefits when added to standard type 2 diabetes care. New research suggests the popular GLP-1 medication Mounjaro may lower the risk of major cardiovascular events, including heart attack, in people with type 2 diabetes and established heart disease. Previous randomized trials have shown that, compared with dulaglutide (Trulicity), tirzepatide (Mounjaro) had similar effects on major cardiovascular events. Major cardiovascular events are a combined measure of heart attack, stroke, and death from any cause. For the new study, researchers analyzed health insurance data from nearly 53,000 people with type 2 diabetes, overweight or obesity, and established h…